https://sputniknews.com/science/202012281081592567-novavax-launches-phase-3-trial-of-its-covid-19-vaccine-in-us/
To date, two COVID-19 vaccines have been approved in the US: one developed by Pfizer and BioNTech, and another made by Moderna. Both of these vaccines use messenger RNA (mRNA) to teach cells how to make a protein that triggers an immune response to COVID-19.
American company Novavax on Monday announced that it has launched a phase 3 trial of its COVID-19 vaccine, making it the fifth company to start a late-stage vaccine trial in the US.
According to a news release from the US National Institutes of Health (NIH), the randomized, placebo-controlled trial will enroll around 30,000 people at around 115 sites in the US and Mexico.
Phase 3 trials begin for Novavax COVID vaccine in US, Mexico
jamaicaobserver.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jamaicaobserver.com Daily Mail and Mail on Sunday newspapers.
COVID-19: Here s what you need to know today
jamaicaobserver.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jamaicaobserver.com Daily Mail and Mail on Sunday newspapers.
Woodbury County on Sunday sees lowest one-day infections tally since early October
siouxcityjournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from siouxcityjournal.com Daily Mail and Mail on Sunday newspapers.
for details. Please do not contact the NIAID media phone number or email to enroll in this trial.
Colorized scanning electron micrograph of an apoptotic cell (blue) infected with SARS-COV-2 virus particles (red), isolated from a patient sample.NIAID
The Phase 3 trial of another investigational coronavirus disease 2019 (COVID-19) vaccine has begun enrolling adult volunteers. The randomized, placebo-controlled trial will enroll approximately 30,000 people at approximately 115 sites in the United States and Mexico. It will evaluate the safety and efficacy of NVX-CoV2373, a vaccine candidate developed by Novavax, Inc., of Gaithersburg, Maryland. Novavax is leading the trial as the regulatory sponsor. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness